MiBA

What MiBA does

MiBA (Meaningful Insights Biotech Analytics) is a Tampa, Florida-based healthcare AI technology company that provides oncology data analytics, clinical trial intelligence, and market insights to pharmaceutical and biotech companies, healthcare providers, and payors. The company was formed in April 2024 as a synergistic joint venture between American Oncology Network (AON), a publicly traded NASDAQ-listed oncology practice network (AONC), and Ascend Technologies Group (ATG), which provides the underlying data science and engineering capability. MiBA operates as a strategic subsidiary of AON and aggregates real-time oncology data from AON's network of 25+ community oncology practices spanning 20 U.S. states.

The MiBA platform consists of four core product lines: MiBA Trials™ (clinical trial intelligence with dynamic cohort building, automated ClinicalTrials.gov protocol digitization, EMR-embedded patient eligibility alerts, and structured/unstructured RWD abstraction covering 200+ biomarkers), Business Intelligence / Market Basket (oncology market dynamics, utilization analytics, prescriber behavior, and competitive positioning), Targeted Education (data-driven provider education including the NCODA-co-developed Oncology Insights Program), and Custom Data Solutions (white-glove bespoke analytics). The technology layer applies natural language processing and large language models to multimodal oncology data — EHR, claims, specialty pharmacy, clinical trials, and genomic data — with claimed precision and recall above 0.9 and nightly data refresh cycles. The platform supports both structured patient data and unstructured clinical text and has produced peer-reviewed publications at the 2025 ASCO Annual Meeting on neoadjuvant HER2 therapy and bispecific antibodies in community oncology settings.

MiBA generates revenue primarily through annual enterprise subscriptions across its four product lines, supplemented by project-based professional services for custom analytics engagements, with custom quote-based pricing and no public rate cards. Distribution combines direct enterprise sales targeting pharma/biotech, providers, and payors with channel partnerships through AON's practice network and co-marketing relationships with precision medicine companies including Guardant Health, Caris Life Sciences, and Foundation Medicine, plus association partnerships (NCODA) and GPO partnerships (AllyGPO). The company is SOC 2 Type 2 certified and operates with a leadership team drawn from both founding partners, supported by a medical advisory board of practicing oncologists.

Name

MiBA

Legal name

Meaningful Insights Biotech Analytics, LLC

Website

https://www.mibanalytics.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

MiBA is a Tampa-based healthcare AI company providing oncology data analytics, clinical trial intelligence, and market insights to pharmaceutical companies, healthcare providers, and payors. It was formed as a 2024 joint venture between American Oncology Network and Ascend Technologies Group.

Ownership category

akta.pro rank

Product category

Oncology Data Analytics

NAICS

Custom Computer Programming Services (541511), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)

SIC

Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)

akta.pro secondary industries

Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN), Data Analytics & Business Intelligence Services (BPAHALAC)

Keywords

• Oncology data analytics
• Clinical trial intelligence
• Real-world evidence platform
• Healthcare AI analytics
• Precision oncology data

Headquarters

HQ city

Tampa

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Trials Platform: MiBA Trials™ Platform provides clinical trial intelligence services including feasibility analysis, site selection, and patient identification for pharmaceutical and biotech companies conducting Phase I, II, and III trials. Revenue generated through subscription or project-based arrangements with pharma/biotech customers.
2. Business Intelligence / Market Basket: Market Basket platform provides oncology market dynamics and competitive intelligence to pharmaceutical companies and healthcare stakeholders. Flexible platform with quarterly filter updates, likely subscription-based access to market insights.
3. Custom Data Solutions: White-glove custom solutions delivering deep market analysis, competitive landscapes, and strategic insights. Revenue generated through project-based consulting engagements with pharmaceutical companies, research organizations, and healthcare providers.
4. Healthcare Provider Data Solutions: Analytics and insights services for healthcare providers including treatment decision support, clinical decision support (TIPS), and operational efficiency tools. Supports personalized treatment plans and predictive modeling.
5. Payor Analytics: Data-driven tools for payors including patient claims data analysis, risk assessment, cost management, network design, and population health management. Revenue from payor contracts for strategic insights.
6. Targeted Education Programs: Provider engagement and education programs including the Oncology Insights Program (OIP), delivering data-driven education to healthcare professionals. Collaboration with organizations like NCODA and Caris Life Sciences.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

MiBA is a healthcare AI technology company that provides oncology data analytics through its unified platform featuring the MiBA Trials™ clinical trial intelligence module, the Market Basket business intelligence solution, a Targeted Education program, and Custom Data Solutions. The platform aggregates real-time multimodal oncology data (EHR, claims, specialty pharmacy, clinical trials, genomic data) from 25+ community oncology practices across 20 states and applies NLP and large language models to surface actionable insights for pharmaceutical companies, biotech firms, oncology providers, and payors.

Product overview

MiBA is a healthcare AI technology company offering a unified analytics platform with multiple integrated modules. The core offerings include: MiBA Trials™ Platform for clinical trial intelligence, Business Intelligence with Market Basket for market analytics, Targeted Education for provider engagement, and Custom Data Solutions for bespoke analytics. The platform aggregates real-time oncology data from diverse sources including Electronic Health Records, claims, specialty pharmacy, clinical trials, and genomic data. The company's AI technology layer employs natural language processing and large language models to extract meaningful insights from unstructured oncology data.

Differentiator

Problem solved

Functional benefit

Brands

• MiBA Trials™ Platform: AI-powered clinical trial platform delivering real-time intelligence for trial feasibility, site selection, patient identification, and protocol digitization.
• Market Basket

Products and services

• MiBA Trials™ Platform AI-powered clinical trial intelligence platform providing real-time feasibility analysis, site selection, rapid patient identification, dynamic cohort building with customizable inclusion/exclusion criteria, interactive patient eligibility alerts within the EMR, automated protocol digitization of ClinicalTrials.gov studies, and monitoring of eligible cases for Phase I, II, and III oncology trials. Built for pharmaceutical and biotech sponsors and oncology providers.
• Market Basket (Business Intelligence) Oncology business intelligence solution providing detailed utilization analytics, geographic distribution insights, treatment pattern analysis, prescriber behavior insights, and competitive positioning data for oncology drugs and indications, with quarterly filter updates to track evolving market dynamics for pharmaceutical companies and healthcare stakeholders.
• Targeted Education Educational offering that delivers real-world data-backed, targeted alerts and insights to healthcare providers, integrating with clinical workflows to close the feedback loop between data analysis and patient care for oncologists and oncology care teams.
• Custom Data Solutions White-glove custom analytics service that transforms complex oncology data into actionable intelligence for pharmaceutical companies, research organizations, and healthcare providers, including comprehensive market analysis, competitive landscape insights, referral pathway analysis, and bespoke real-time data processing with expert analyst support.
• Oncology Insights Program (OIP) Joint educational program with NCODA providing medically integrated oncology professionals with actionable insights and targeted education powered by real-time prescriber data to support data-driven decision-making.

Quantifiable outcome

• Reduction in clinical trial duration through optimized patient recruitment and site selection
• +3 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered minor, core and flagship.

• Oklahoma Cancer Specialists and Research Institute (OCSRI)minorChannel Partner/ Reseller/ Distributor · 30 April 2026Strategic partnership integrating MiBA's real-time data platform into OCSRI's clinical operations. Enables physicians to access actionable insights for treatment planning and clinical trial matching at point of care. Aims to shorten time from study feasibility to first patient enrollment for Phase I, II, and III trials.
• Oncology ConsultantsminorChannel Partner/ Reseller/ Distributor · 29 April 2026Strategic partnership to enhance precision oncology using AI-driven analytics for cancer care in Houston area. Collaboration leverages MiBA's AI platform and Trials technology to improve treatment decisions, biomarker optimization, operational efficiency, and clinical trial access for patients in Southeast Texas.
• AllyGPOminorGTM or Marketing Partner · 8 January 2026Strategic partnership to enhance community oncology practices with real-world data and analytics. Leverages MiBA's AI-powered clinical insights and AllyGPO's contracting and drug management platform with pipeline of partners and therapies planned for 2026.
• Caris Life SciencescoreStrategic or Co-development Partner · 24 April 2025Strategic collaboration to provide physician education and insights to accelerate research and personalize treatment plans. Integrates MiBA's technology with Caris' multimodal database for precise, personalized treatment options. MiBA's targeted alerts guide oncologists to appropriate molecular testing including Whole Exome Sequencing and Whole Transcriptome Sequencing.
• Guardant HealthcoreTechnology or Integration · 20 December 2024Strategic partnership to optimize biomarker testing and data analytics to advance precision medicine. Combines MiBA's AI technologies and oncology data with Guardant's comprehensive tumor profiling and ctDNA monitoring. Equips stakeholders with knowledge about biomarker testing and cancer monitoring tools.
• NCODA (National Community Oncology Dispensing Association)coreGTM or Marketing Partner · 22 October 2024Joint Oncology Insights Program (OIP) providing healthcare professionals with actionable insights and targeted education. NCODA leads educational material development while MiBA provides real-time data and actionable insights. Program runs throughout 2025 with full launch in January.
• Foundation MedicinecoreTechnology or Integration · 26 June 2024Partnership to expand awareness and education on comprehensive genomic profiling (CGP) in community oncology. MiBA helps Foundation Medicine execute CGP-related education programs for practices within the American Oncology Network, advancing genomic data integration into everyday cancer treatment.
• American Oncology Network (AON)flagshipStrategic or Co-development Partner · 1 April 2024MiBA was created as a synergistic partnership between American Oncology Network (AON) and Ascend Technologies Group (ATG). AON provides the oncology network and clinical expertise while MiBA serves as the data analytics subsidiary. MiBA's platform leverages AON's network of 25+ community oncology practices across 20 states for data collection and distribution of analytics services.
• Ascend Technologies Group (ATG)flagshipStrategic or Co-development Partner · 1 April 2024MiBA was created as a synergistic partnership between Ascend Technologies Group (ATG) and American Oncology Network (AON). ATG provides technology and data science expertise while MiBA serves as the oncology analytics platform. Jason Baroff, Managing Partner at ATG, leads MiBA's technology platform development.
• Cellectar BiosciencescoreStrategic or Co-development Partner · 11 January 2024Partnership to advance Waldenstrom's Macroglobulinemia (WM) treatment in the community oncology setting. MiBA provides data on WM treatment landscape and community clinic access to support Cellectar's Iopofosine I-131 commercialization strategy.

Scale indicators6 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Syapse: Oncology real-world evidence company partnering with community health systems and IDNs to deliver precision medicine insights to pharma. Comparable in serving community oncology with RWE and clinical decision support use cases.
• Tempus Labs: AI-powered precision medicine platform combining genomic sequencing, clinical data, and AI analytics for oncology and other therapeutic areas. Competes with MiBA in pharma-grade oncology data, biomarker analytics, and clinical trial optimization.
• COTA Healthcare: Oncology-focused real-world evidence and analytics company serving providers, pharma, and payors with curated oncology data. Direct overlap with MiBA's RWE, market access, and provider decision support offerings.
• ConcertAI: AI-driven oncology real-world evidence and clinical trial solutions company serving top 20 pharma sponsors. Direct competitor in the same pharma-funded RWE and clinical trial intelligence space MiBA targets.
• Flatiron Health: Roche-owned oncology-specific EHR and real-world evidence platform serving community oncology practices, academic centers, and pharma sponsors. Most direct competitor to MiBA given overlapping focus on oncology RWE, clinical trial patient identification, and pharma-grade data products.

Broad incumbents

• IQVIA: Global clinical research services, RWE, and healthcare data analytics giant. Overlaps with MiBA in oncology clinical trial site selection, patient recruitment, RWE studies, and market access analytics, though as part of a much broader portfolio.
• Medidata Solutions (Dassault Systèmes): Clinical trial technology platform (Rave, Acorn AI) serving pharma and CROs. Competes with MiBA Trials™ in clinical trial feasibility, site selection, and patient identification, though focused across all therapeutic areas.

Emerging players

• Guardant Health: Liquid biopsy and precision oncology company that is both a MiBA strategic partner and a partial competitor — Guardant360, Reveal, and biopharma services overlap with parts of MiBA's biomarker analytics and pharma intelligence offerings.
• Caris Life Sciences: Molecular profiling and AI-driven precision medicine company offering MI Profile, MI Cancer Seek, and a biopharma services business. Overlaps with MiBA in oncology molecular profiling data and pharma partnerships (and is itself a MiBA partner).
• Foundation Medicine: Roche subsidiary offering comprehensive genomic profiling and a growing data and biopharma services business. Both a MiBA partner and adjacent competitor in the oncology data and biomarker intelligence space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mibanalytics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MiBA